• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / RESEARCH . . . . / Human Papillomavirus Research / Norwegian Institute for Public Health: Large National HPV Study Underway

Norwegian Institute for Public Health: Large National HPV Study Underway

February 5, 2011 By Norma

A simple urine test can provide important answers
Published  03 February 2011

The first 17-year-old girls are now receiving an invitation to participate in a pilot study in advance of a planned nationwide research on the prevalence of human papillomavirus (HPV). Urine samples will be collected and tested for HPV. The purpose is to get more detailed knowledge about the prevalence of HPV and the types of the virus which are present in the population.

The project is part of a comprehensive compliance program, HPVnorvaks, which is implemented in conjunction with the introduction of HPV vaccine to young girls.

There are many different types of HPV. Most are harmless, but some can cause cancer, particularly cervical cancer. Human papillomavirus is very common in the population. Most people get rid of the virus by itself, but in some cases the virus causes persistent infection and can cause cell changes and cervical cancer. In order to prevent cervical cell changes and cervical cancer the HPV vaccine was added to the children’s vaccination program  in 2009. The vaccine protects against the most common cancer-causing HPV and is offered to all girls in 7 class.

“- What we now want to gain knowledge about is the prevalence of HPV in different age groups in the population. This will give us an important basis for comparison in the future when we will do similar studies to document the efficacy of HPV vaccine,” says consultant and project manager Lill Trøgstad at the NIPH.

– We will monitor whether the introduction of HPV vaccine changes the incidence of different HPV types in the population. Will the types the vaccine protects against disappear? Can other types take over the space of these? These are issues we want to answer as the proportion of vaccinated women is greater.“- In this pilot study it is young women of 17 years who are invited. All one needs do is submit a consent form and a urine sample. No long questionnaires to be filled this time, ” said Trøgstad.

In the survey samples will be tested for 40 different types of the virus.

“- Since HPV is so common and most people get rid of their HPV infection by itself, will the findings of HPV in urine have no significance for the individual participant. The test results are primarily useful to look at incidence in the population and whether there will be changes in incidence over time. By participating you will help provide valuable knowledge about the prevalence of HPV among young women. Such knowledge is important for improving women’s health, ” said Trøgstad.

The project is part of a comprehensive compliance program, HPVnorvaks.

Norway is in the fortunate situation that we have a unique opportunity to follow up and study the impact of HPV vaccination in young girls. Data from this survey, combined with data from, among other things, immunization registry SYSVAK and Cancer Registry, give us insight into this. This follow-up will continue for many years and involve several different research projects. Public Health, Cancer Registry and the HPV reference laboratory at the Akershus University Hospital is responsible for monitoring program and research projects that are included.

View original language version here.

Related

Filed Under: Human Papillomavirus Research Tagged With: HPV prevalence, Norway

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Gardasil changed our dreams to nightmares

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

You Don’t Want To Know What’s In Your Flu Shot!

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in